Telethink Health gtag('config', 'UA-191548160-2');
Menu

Telethink a TeleHealth Care Convener

Establishing Affordability and Accessibility for Employers, Providers and Families

covid rapid test me

 

COVIDRAPIDTESTME.COM

 

The tests can be executed quickly at home or, at scale for: employers, providers, airports, hospitals, stadiums and schools. It answers the question, am I infectious?

 

 COROWELL USA

The world needs an easy, non-invasive, cost-effective screening test – we have it.

 

 

 

 

Anosmia (partial or complete loss of the sense of smell) is the most suitable indicator for early COVID-19 detection and occurs in 86% of cases. It often develops early (first five days) after exposure to infections at the onset of the contagious phase. This is the most important time to detect the infection to break infection chains.

The objective of pooling is to get swift, widespread results that can help stop or mitigate outbreaks. The results as compared to a PCR nose swab are:

 

High Sensitivity Rate (96.4% pooled) Sensitivity is the percentage of actual positive cases that are correctly identified as positive.

High Specificity Rate (91.1% pooled) Specificity is the percentage of people who will correctly test negative out of all people who are negative.

Capable of Detection across all Variants

Early Detection-First Five Days of Infection

Filters for “infection-suspects”

 

To date, the only valid test to detect the presence of the virus is the reverse transcription-polymerase chain reaction (RT-PCR), usually with a nasopharyngeal swab. It's sensitivity varies with the specimen types, and is more specific if anosmia is present.

The main problems with RT-PCR are its expensive price and a specific and protected structure in which to utilize the swab.

Another problem is its efficiency in mass testing with few positive results (most of the time under 10%) In other words, fewer false positives.

An urgent need exists to find a simpler and cheaper solution to diminish the number of RT-PCR negative tests.

Based on Clinical/Scientific Evidence, Stanford Univ.FDA Registered Medical Device, OSHA Approved

 

To Schedule a Call or Receive a Free Quote: Please Message Rob Gillespie  telethink@protonmail.com . Anytime *Wholesale pricing based on volume.

Packaging:

Single test

      

The COROWELL Rapid & Objective, COVID-19 Symptom Screening Test is eligible for reimbursement for insurance with the following codes: CPT 99202 (new patients), CPT 99212 (established patients). Eligible for purchase with the CARES Act and for reimbursement under Medicare.

 

 

 

 

 

 

 

 

;